News
High Standards
24. July 2019
EU 4 health
9. December 2020
Pharmaceutical Strategy
On Wednesday 25 November 2020, the European Commission has published its long awaited Communication setting out a new “Pharmaceutical Strategy for Europe”.
Europe’s Pharmaceutical Strategy has four main objectives:
- Ensuring access to affordable medicines for patients, and addressing unmet medical needs (e.g. in the areas of antimicrobial resistance, cancer, rare diseases);
- Supporting competitiveness, innovation and sustainability of the EU’s pharmaceutical industry and the development of high quality, safe, effective and greener medicines
- Enhancing crisis preparedness and response mechanisms, and addressing security of supply;
- Ensuring a strong EU voice in the world, by promoting a high level of quality, efficacy and safety standards.
The launch was preceded by a consultation round for stakeholders, where ESOP has given extensive input.
Since the pharmaceutical strategy also comprises adaptation of the pharmaceutical European legislative framework, the action of the upcoming years could potentially be very beneficial for all in the area of health-care, including oncology. We will continu to seek collaboration with the EU Sante and the MEPs involved in this work.
Ukraine
2. March 2020
Liaisons
 | Bogdan Larin, Kyiv LLC Yuria-Pharm Oncology Pharmacy Email: bl[at]esop.li |
 | Victoria Zapotochna, Kyiv Tory Group Ukraine LLC Website: Tory Group Email: vz[at]esop.li |
Current Information
Mexico
19. January 2020
Delegates
 | Oscar Angel Morales Bustamante Email: oamb[at]esop.li |
| Jose Alberto Castillo Figueroa Email: jacf[at]esop.li |
  | Sandra Antonieta Palacios García Email: spg[at]esop.li |
Current Information
Ivory Coast
Liaison
 | Gaoussou Meite, Abidjan Email: mg[at]esop.li |
Current Information
Case Reports
7. January 2020
To create a new Case Report, please use the following templates:
Open / Download Actual Case Reports
| Titel | Download |
|---|---|
| Extravasation; Prevention and Treatment Approaches | Casereport 1/15 (clinical) |
| Elder Patients Enagement and Adherence Diagnosed With Metatstatic Renal Cell Carcinoma | Casereport 2013 (practise) |
| Multiple myeloma (plasmocytoma) with FUO and mucositis after autologous stem cell transplantation | Casereport 06 (clinical) |
| Pancytopenia and oesophageal thrush after irradiation and palliative chemotherapy of adenocarcinoma of the lung (NSCLC) | Casereport 05 (clinical) |
| Underststanding and Consulting Menopause & chemotherapy | Casereport 04/12 (practise) |
| Therapy and supportive care of a high-grade-non-Hodgkin’s lymphoma | Casereport 04 (clinical) |
| Adjuvant and palliative treatment of carcinoma of the sigmoid colon | Casereport 03 (clinical) |
| A 59 years old man with stage IV malign lung carcinoma | Casereport 04/11 (practise) |
| Adjuvant treatment of carcinoma of the sigmoid colon | Casereport 02 (clinical) |
| A 69 years old woman with stage IV small cell lung carcinoma | Casereport 12/10 (practise) |
| Non-small cell lung adenocarcinoma (NSCLC) with lung metastasis and lymphangitis carcinomatosis, stage IV | Casereport 01 (clinical) |
| 53 years old female patient with Stage IV Breast Carcinoma Lung Metastasis | Casereport 11/10 (practise) |
EJOP
20. December 2019
The European Journal of Oncology Pharmacy
The European Journal of Oncology Pharmacy is a peer-reviewed pharmaceutical journal in the field of cancer treatment. The journal encompasses all the recent issues related to the role of pharmacists in the prevention and treatment of cancers under its scope. This includes basic and applied researches on the synthesis or extraction, compounding, analysis, stability, pharmacology, side-effects, and clinical use of anticancer drugs and adjuvants therapies such as antiemetic, analgesic, or complementary medicines.
Now Open for Manuscript Submissions
European Journal of Oncology Pharmacy now seeks top-quality articles from the global research community which will aid in achieving high impact factor and largest diffusion. Authors are encouraged to share their ideas and valuable research outcomes through this Journal and provide the global readers updated and most important information in the mode of original articles, review articles, case reports, and short communications.
Benefits to Publishing in European Journal of Oncology Pharmacy!
- No submission fees
- Own the copyright to your work
- Clear ethical guidelines
- Compliant with open access funding mandates
More info at www.editorialmanager.com/EJOP
Yellow Hand
12. December 2019
Drugs with carcinogenic, mutagenic and/ or reproductive toxicity must must be handled with caution. Promoting Quality Standards for the Oncology Pharmacy Service ESOP offers a guideline for the transport of highly potent drugs and practical help.
Suppliers are asked to take precautions to avoid:
-breakage (e.g. plastic bottles instead of glass bottles)
-external contamination (e.g. cleaning, outer wrapping)
Thus, for the delivery of any cmr-drugs QuapoS guidelines insist on the following:
-secured, sealed, leak-proof cases
-a separate delivery
-clear labeling (in the spoken language of the recipient)
Labels should indicate:
-a warning of the highly potent drug
-that contact must be avoided
-that pregnant or breastfeeding women must not handle the product
-an emergency contact in case of spillage
News from Austria:
Standards für das Gebrauchsfertigmachen, die Applikation
und die Entsorgung von Zytostatika
Detailed Information
Labels Yellow Hand
ECOP
5. December 2019
The European Conference of Oncology Pharmacy will provide a distinct multi-professional setting and multidisciplinary approach to promote the highest standards of pharmaceutical care in the management and support of patients with tumours.
The programme aims to equip oncology pharmacy practitioners with knowledge about recent developments, advance the effectiveness of healthcare delivery and increase the quality of patient care. State-of-the-art advances in research, patient management and practice will be showcased in keynote lectures, scientific symposia and poster sessions in two well-defined tracks: clinical and practical.
Target Audience
This conference attracts multiple stakeholders: oncology pharmacists, hospital pharmacists, community pharmacists, medical oncologists, oncology physicians, pharmacy nurses, pharma industry.
Read more about the next ECOP ->
